Company: NIVFW
Filing Date: 2025-08-22
Form Type: DRS
Source: 0001213900-25-079717
Chunk: 132

Company: NewGenIvf Group Ltd
Filing Date: 2025-08-22
Form: DRS
Chunk 132
---
) | allocate the transaction prices to its performance obligations in those contracts; and |

| (5) | recognize revenue when each performance obligation under those contracts is satisfied. Revenue is recognized when promised services are transferred to the client in an amount that reflects the consideration expected in exchange for those services. |

The Company enters into verbal
agreements with its customers that outline the rights, responsibilities, and obligations of each party. The agreements also identify the
scope of services, service fees, and payment terms. Agreements are acknowledged and consent forms are signed by the customers prior to
each promised service or bundle of services that are inter dependent. All the contracts have commercial substance, and it is probable
that the Company will collect considerations from its customers for service component as settlement is predominantly required prior to
performance of the promised service.

The Company derives its revenues
from two sources: (1) revenue from IVF treatment, and (2) revenue from surrogacy and ancillary caring services.

Revenue from IVF treatment

In vitro fertilization (“IVF”)
treatment is an assisted reproductive technique where eggs and sperm are collected and fertilized in laboratory to become embryo. Fertilized
embryo is then implanted to the customer or a surrogate mother. IVF treatment involves the performance of a series of medical treatment
as well as procedures and brings benefits to clients as the service of bundles service is completed. Revenue from IVF treatment is recognized
at a point in time when different treatment and/or procedure or bundles thereof, are completed in clinic. The full completion of the various
procedures and treatments are evidenced by treatment cards and reports included within the patient files indicating successful completion
of the service.

<div align='center'>74</div>

Revenue from surrogacy and ancillary caring services

The Company provides surrogacy
and ancillary caring services solely in Kyrgyzstan. Embryo from blood parents is implanted to surrogate mother contracted by the Company
or its agents. During pregnancy period, the Company provides ancillary caring services including regular body check and provision of vitamins,
supplements and medicines to surrogate mothers. The key performance obligation is identified as a single performance obligation where
a baby is born, therefore revenue from surrogacy and ancillary caring services is recognized at a point in time when surrogate mother
gives birth. The Company collects approximately 40% of contract sum upfront, and remaining contract sum is collected in installments across
pregnancy period of surrogate mother. The amount of revenue recognized from contract liabilities to